Article
CEBPA mutational analysis in acute myeloid leukaemia by a laboratory-developed next-generation sequencing assay.
Journal of clinical pathology - 1 Jun 2018
Ng Christopher Wai Siong, Kosmo Bustamin, Lee Peak-Ling, Lee Chun Kiat, Guo Jingxue, Chen Zhaojin, Chiu Lily, Lee Hong Kai, Ho Sherry, Zhou Jianbiao, Lin Mingxuan, Tan Karen M L, Ban Kenneth H K, Tan Tin Wee, Chng Wee Joo, Yan Benedict
Abstract excerpt
AIM: The presence of biallelic CEBPA mutations is a favourable prognostic feature in acute myeloid leukaemia (AML). CEBPA mutations are currently identified through conventional capillary sequencing (CCS). With the increasing adoption of next-generation sequencing (NGS) platforms, challenges with regard to amplification efficiency of CEBPA due to the high GC content may be encountered, potentially resulting in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.